1[1]Morrish PK, Sawle GV, Brooks DJ.Clinical and [18F]dopa PET fi ndings in early Parkinson's disease.J Neurol Neurosurg Psych,1998,59(6):597
2[2]Antonini A, Vontobel P, Psylla M, et al.Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol,1995,52(12):1183
3[3]Piccini P, Morrish PK, Turjanski N, et al.Dopaminergic function in fam ilial Parkinson's disease: a clinical and 18F-dopa PET study.Ann Neurol,1997,41 (2):222
4[4]Laihinen A, Ruottinen H, Rinne JO, et al.Risk for Parkinson's disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodo pa PET.J Neurol,2000,247(Suppl 2):Ⅱ110
5[5]Morrish PK, Rakshi JS, Sawle GV, et al.Measuring the rate of progressio n and estimating the preclinical period of parkinson's disease with [18F]dop a PET.J Neurol Neurosurg Psych,1998,64(3):314
6[6]Caparros D, Cabaret M, Codefroy O, et al.PET study and neuropsychologic al assessment of a long-lasting post-encephalitic parkinsonism.J Neural Transm ,1998,105(2):489
7[7]Turjanski N, Lees AJ, Brooks DJ, et al.Dopaminergic function in patient s with posttraumatic parkinsonism: an 18F-dopa PET study.Neurology,1997,49(1):1 83
8[8]Burn DJ, Brooks DJ.Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study.Neurology,1993,43(3):552
9[9]Defer GL, Geny C, Ricolfi F, et al.Long-term outcome of unilaterally t ransplanted parkinsonian patients: I clinical approch.Brain,1996,119(1):41
10[10]Torstenson R, Hartvig P, Lungstrom B, et al.Differential effects of le vodopa on dopaminergic function in early and advanced Parkinson's disease.Ann Ne urol,1997,41(3):334
